Success Metrics

Clinical Success Rate

88.9%

Based on 16 completed trials

Completion Rate

89%(16/18)

Active Trials

3(14%)

Results Posted

31%(5 trials)

Terminated

2(10%)

Phase Distribution

Ph phase_4

10%

Ph phase_2

43%

Ph not_applicable

Ph phase_3

14%

Ph phase_1

29%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution21 total trials

Phase 1Safety & dosage

6(28.6%)

Phase 2Efficacy & side effects

9(42.9%)

Phase 3Large-scale testing

3(14.3%)

Phase 4Post-market surveillance

2(9.5%)

N/ANon-phased studies

1(4.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

16 of 18 finished

Non-Completion Rate

11.1%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(16)

Terminated(2)

Detailed Status

Completed16

Recruiting3

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.9%

Most Advanced

Phase 4

Trials by Phase

Phase 16 (28.6%)

Phase 29 (42.9%)

Phase 33 (14.3%)

Phase 42 (9.5%)

N/A1 (4.8%)

Trials by Status

terminated210%

recruiting314%

completed1676%

Recent Activity

3 active trials

Showing 5 of 21

recruitingphase_2

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

NCT05053503

recruitingphase_2

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

NCT04360681

View all 21 trials

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more

NCT05511909Phase 2

Evaluating Buspirone to Treat Opioid Withdrawal

Recruiting

NCT04325659Phase 2

An Innovative Intervention for OUD Treatment

Completed

NCT05027919Phase 2

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Recruiting

NCT05053503Not Applicable

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

Completed

NCT04360681Phase 2

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Recruiting

NCT03718065Phase 2

Impact of Lofexidine on Stress, Craving and Opioid Use

Completed

NCT04070157Phase 2

Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal

Terminated

NCT05569031Phase 4

Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse

Completed

NCT02363998Phase 3

Open-Label, Safety Study of Lofexidine

Completed

NCT01020019Phase 2

Combined Pharmacotherapy for Cannabis Dependency

Completed

NCT02681198Phase 1

Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers

Completed

NCT00000358Phase 1

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

Completed

NCT00000354Phase 1

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3

Completed

NCT00032942Phase 3

Lofexidine for Opiate Withdrawal - 1

Completed

NCT00000345Phase 1

Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10

Completed

NCT00218530Phase 1

Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1

Completed

NCT01148992Phase 1

Interactions Between Intravenous (IV) Cocaine and Lofexidine

Terminated

NCT01675648Phase 4

Lofexidine for Inpatient Opiate Detox in Singapore

Completed

NCT00142909Phase 2

Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1

Completed

NCT00373503Phase 2

Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 21